Galena's Breast Cancer Vaccine Doomed to Fail
Experimental therapies with blockbuster potential don't sit on a shelf for years by accident. They're noticed and bought. NeuVax is not one of these exciting, lucrative therapies. It sat unloved because the data generated from the phase II study don't justify further development.
I'm sure the management team inside RXi/Galena knows this, but they're certainly not going to divulge NeuVax's dirty little secret because they need retail investors continue buying the stock.
With three more years at least before NeuVax fails, Galena management has a lot more stock to sell and millions of dollars in paychecks to cash.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein.
>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.
>To submit a news tip, send an email to: firstname.lastname@example.org.